XYLOCAINE 2% W EPINEPHRINE 1:100000 0.01 MG — DIN 00001821
EPINEPHRINE (EPINEPHRINE BITARTRATE) : 0.01 MG LIDOCAINE HYDROCHLORIDE : 20 MG · ASTRAZENECA CANADA INC · LIQUID · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is XYLOCAINE 2% W EPINEPHRINE 1:100000?
XYLOCAINE 2% W EPINEPHRINE 1:100000 0.01 MG contains EPINEPHRINE (EPINEPHRINE BITARTRATE) : 0.01 MG LIDOCAINE HYDROCHLORIDE : 20 MG. It is listed in the Health Canada Drug Product Database under DIN 00001821, held by ASTRAZENECA CANADA INC, supplied as LIQUID for BLOCK/INFILTRATION administration. Health Canada currently lists it as cancelled post market, status dated 12-Sep-2012. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
What is XYLOCAINE 2% W EPINEPHRINE 1:100000 used for?
XYLOCAINE Parenteral Solutions (lidocaine hydrochloride) are indicated for production of local or regional anesthesia by infiltration techniques including percutaneous injection, peripheral nerve block techniques such as brachial plexus and intercostal blocks, and central neural techniques including epidural and caudal blocks, when the accepted procedures for these techniques, as described in standard textbooks, are observed.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Lidocaine, Combinations in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
21 holders have a Canadian DIN containing Lidocaine, Combinations, across 72 DINs, of which 16 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SEPTODONT | 6 | 5 | LIDOCAINE 2% AND EPINEPHRINE 1:100,000, LIDOCAINE 2% AND EPINEPHRINE 1:50,000, LIGNOSPAN FORTE, LIGNOSPAN SPECIALE INJ, LIGNOSPAN STANDARD, +1 more | Sourceable in Canada |
| ASPEN PHARMACARE CANADA INC. | 4 | 4 | XYLOCAINE 1% W EPINEPHRINE 1:100000, XYLOCAINE 1% W EPINEPHRINE 1:200000, XYLOCAINE 2% W EPINEPHRINE 1:200000, XYLOCAINE 2% WITH EPINEPHRINE 1:200000 | Sourceable in Canada |
| DENTSPLY CANADA LIMITED | 4 | 2 | DENTSPLY 2% LIDOCAINE WITH EPINEPHRINE 1:100,000, DENTSPLY 2% LIDOCAINE WITH EPINEPHRINE 1:50,000, XYLOCAINE DENTAL LIDOCAINE HCL 2% AND EPINEPHRINE 1:100,000, XYLOCAINE DENTAL LIDOCAINE HYDROCHLORIDE 2% AND EPINEPHRINE 1:50,000 | Sourceable in Canada |
| NOVOCOL PHARMACEUTICAL OF CANADA INC | 3 | 1 | OCTOCAINE 100 NEEDLEJECT INJ, OCTOCAINE HCL 2% EPINEPHRINE 1:100000, OCTOCAINE HCL 2% EPINEPHRINE 1:50000 | Sourceable in Canada |
| PFIZER CANADA ULC | 3 | 1 | LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | Sourceable in Canada |
| HIKMA CANADA LIMITED | 1 | 1 | LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | Sourceable in Canada |
| PENDOPHARM DIVISION OF PHARMASCIENCE INC | 1 | 1 | INSTILLAGEL | Sourceable in Canada |
| SCIENCES DE LA PEAU CRESCITA INC. / CRESCITA SKIN SCIENCES INC. | 1 | 1 | PLIAGLIS | Sourceable in Canada |
| BAXTER CORPORATION | 14 | 0 | CONTINUOUS EPIDURAL ANESTHESIA TRAY, EPIDURAL ANESTHESIA TRAY, PARACENTESIS TRAY W BOASBERG CATHETER SET, SINGLE-SHOT EPIDURAL ANESTHESIA TRAY, SPINAL ANAESTHESIA TRAY, +1 more | No marketed DIN |
| ARROW INTERNATIONAL INC. | 11 | 0 | ARROW CENTRAL VENOUS CATHETERIZATION KIT, ARROW MULTI-LUMEN CENTRAL VENOUS CATHETER KIT, ARROW PNEUMOTHORAX KIT, ARROW TWO-LUMEN CENTRAL VENOUS CATHETAR KIT, ARROW TWO-LUMEN JUGULAR CATHETERIZATION KIT, +6 more | No marketed DIN |
| ASTRAZENECA CANADA INC | 5 | 0 | XYLOCAINE 0.5% W EPINEPHRINE 1:100000, XYLOCAINE 0.5% W EPINEPHRINE 1:200000, XYLOCAINE 1.5% W EPINEPHRINE 1:200000, XYLOCAINE 1.5% W EPINEPHRINE 1:200000 TEST DOSE, XYLOCAINE 2% W EPINEPHRINE 1:100000 | No marketed DIN |
| ALLEGIANCE HEALTHCARE CORPORATION | 3 | 0 | GENETIC AMNIOCENTESIS TRAY KIT, JAMSHIDI BONE MARROW BIOPSY TRAY, JAMSHIDI MENGHINI SOFT TISSUE BIOPSY TRAY | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 0.01 MG |
|---|---|
| Dosage form | LIQUID |
| Route | BLOCK/INFILTRATION |
| Pack configuration (monograph) | null |
| Storage | null |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Lidocaine, Combinations |
|---|---|
| ATC code | N01BB52 |
| AHFS class | 72:00.00 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 00001821 |
|---|---|
| DIN (unpadded, as printed on some documents) | 1821 |
| Brand name | XYLOCAINE 2% W EPINEPHRINE 1:100000 |
| Generic / active ingredient | EPINEPHRINE (EPINEPHRINE BITARTRATE) : 0.01 MG LIDOCAINE HYDROCHLORIDE : 20 MG |
| Market authorization holder | ASTRAZENECA CANADA INC |
| Health Canada schedule | Ethical |
| ATC code | N01BB52 |
| ATC anatomical main group | N — Nervous system |
| ATC therapeutic subgroup | N01BB |
| Current status | CANCELLED POST MARKET |
| Status date | 12-Sep-2012 |
| Original market date | 1955-12-31 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
16 of 72 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| INSTILLAGEL | 0.05 % | GEL | PENDOPHARM DIVISION OF PHARMASCIENCE INC | MARKETED | 02294990 |
| LIDOCAINE 2% AND EPINEPHRINE 1:100,000 | 20 MG | SOLUTION | SEPTODONT | MARKETED | 02473518 |
| LIDOCAINE 2% AND EPINEPHRINE 1:50,000 | 20 MG | SOLUTION | SEPTODONT | MARKETED | 02473526 |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 20 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 01901915 |
| LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE INJECTION USP | 0.01 MG | SOLUTION | HIKMA CANADA LIMITED | MARKETED | 02436221 |
| LIGNOSPAN FORTE | 36 MCG / 1.8 ML | SOLUTION | SEPTODONT | MARKETED | 00375799 |
| LIGNOSPAN STANDARD | 36 MG / 1.8 ML | SOLUTION | SEPTODONT | MARKETED | 00375780 |
| OCTOCAINE HCL 2% EPINEPHRINE 1:100000 | 0.01 MG | SOLUTION | NOVOCOL PHARMACEUTICAL OF CANADA INC | MARKETED | 00151866 |
| PLIAGLIS | 7 % | CREAM | SCIENCES DE LA PEAU CRESCITA INC. / CRESCITA SKIN SCIENCES INC. | MARKETED | 02398028 |
| XYLOCAINE 1% W EPINEPHRINE 1:100000 | 10 MG | SOLUTION | ASPEN PHARMACARE CANADA INC. | MARKETED | 00001791 |
2 · Same class — other molecules in ATC N01BB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Lidocaine | AMNIOCENTESIS TRAY 1% · ANTECUBITAL CENT VENOUS CATHETERIZATION KIT · ARTHROGRAM TRAY 1% · ATELOCOLLAGEN IMPLANT · +39 more | 72 | 26 | Yes |
| Lidocaine, Combinations | 2% LIDOCAINE AND EPINEPHRINE 1:100,000 INJECTION USP · 5% XYLOCAINE MPF WITH GLUCOSE 7.5% INJECTION · ARROW CENTRAL VENOUS CATHETERIZATION KIT · ARROW MULTI-LUMEN CENTRAL VENOUS CATHETER KIT · +55 more | 72 | 16 | Yes |
| Articaine, Combinations | 4% ASTRACAINE DENTAL WITH EPINEPHRINE 1:200,000 (0.005MG/ML) · 4% ASTRACAINE DENTAL WITH EPINEPHRINE FORTE 1:100,000 (0.01MG/ML) · ARTICAINE HYDROCHLORIDE AND EPINEPHRINE BITARTRATE INJECTION · ORABLOC 1:100,000 · +10 more | 18 | 12 | Yes |
| Bupivacaine | BUPIVACAINE HEAVY INJECTION BP · BUPIVACAINE HYDROCHLORIDE IN DEXTROSE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP · BUPIVACAINE HYDROCHLORIDE INJECTION USP .25% · +12 more | 42 | 10 | Yes |
| Mepivacaine | 3% POLOCAINE DENTAL · CARBOCAINE 1% · CARBOCAINE 2% · CARBOCAINE 3% · +7 more | 15 | 7 | Yes |
| Ropivacaine | NAROPIN · NAROPIN INJ 7.5MG/ML · ROPIVACAINE HYDROCHLORIDE INJECTION · ROPIVACAINE HYDROCHLORIDE INJECTION USP · +2 more | 13 | 6 | Yes |
| Bupivacaine, Combinations | BUPIVACAINE HCL 0.5% AND EPINEPHRINE 1:200,000 INJECTION · MARCAINE · MARCAINE 0.5% AND EPINEPHRINE 1:200,000 LIQ · MARCAINE E · +5 more | 12 | 5 | Yes |
| Prilocaine, Combinations | 4% CITANEST FORTE DENTAL WITH EPINEPHRINE 1:200,000 · DENTSPLY 4% PRILOCAINE AND EPINEPHRINE INJECTION 1:200,000 · EMLA CREAM · EMLA PATCH · +1 more | 5 | 4 | Yes |
| Combinations | CETACAINE LIQUID · ORAQIX | 2 | 2 | Yes |
| Prilocaine | 4% CITANEST PLAIN DENTAL · DENTSPLY 4% PRILOCAINE HYDROCHLORIDE DENTAL INJECTION | 2 | 1 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC N01B
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| N01BA | Benzocaine · Chloroprocaine · Combinations,Of Anesthetics · Procaine · Tetracaine | 13 | 1 |
| N01BX | Phenol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is XYLOCAINE 2% W EPINEPHRINE 1:100000 called?
The same molecule, Lidocaine, Combinations, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Xylocain Dental adrenalin | Latin | Iceland |
| Lident | Latin | Iceland |
| Lidocaina/Epinefrina Normon | Latin | Iceland |
| Lidokain-tetrakain - forskriftarlyf | Latin | Iceland |
| Xylocain adrenalin | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
What is Lidocaine called in other languages?
Buyers, prescribers and procurement teams outside Canada often search for the ingredient in their own script. These are phonetic renderings of the ingredient name Lidocaine, published to help those searches reach this page.
| Language | Lidocaine |
|---|---|
| Chinese (Simplified) 简体中文 | 利多卡因 |
| Russian Русский | лидокаин |
| Spanish Español | lidocaína |
| French Français | lidocaïne |
| Portuguese Português | lidocaína |
| German Deutsch | Lidocain |
| Hindi हिन्दी | लिडोकेन |
| Persian فارسی | لیدوکائین |
| Turkish Türkçe | lidokain |
| Japanese 日本語 | リドカイン |
| Korean 한국어 | 리도카인 |
| Italian Italiano | lidocaina |
These are transliterations of the ingredient name, generated automatically and published only where two independent checks agreed. They are not registered local trade names and carry no marketing authorisation in any market. Always confirm a product against its local registration before ordering.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.